Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Jan 12, 2021 1:00pm
170 Views
Post# 32276823

RE:I've got a bridge to sell them

RE:I've got a bridge to sell themMy earlier hopes were not right. This is just a bad deal in every respect as best I can tell at this point.

Just take a look at the deals AKRO, NGM and ETNB have done in the last little while and ask yourself why our company with similar or even better prospects and NASH positioning (at least in ETNB and AKRO's case - NGM is better positioned than THTX) could not do a deal like the ones those companies were able to pull off?

Now, we all new there was a financing in the company's future and I hoped the dilution would be more in the 10-15% range. So, this deal loads another 20% or so dilution on top of that. If you thought the stock had a chance to rise to $20 in the longer term before, now that price is around $16. Clearly, it is still a good situation but legacy shareholders are paying a hefty price for management's inability to position the company as well as other NASH company management teams have positioned their stocks. It just smacks of a desperate move to grab cash while it was easily avaialable. I thnk they wanted to do this since they first announced the general NASH news in September and they just could not let it go. If they were confident of the company's situation, they would not have needed to do a bad deal. I am confident about the company's situation but maybe they know something I don't that made them jump at a bad deal. While that could easily not be the case, but it is inescapable that such a thought will now linger over the stock for a while.

SABBOBCAT wrote: I hope that SPCEO is right about there being more to the story, because if not I am worried about what they will do with the cash... If a handful of B and C rated Canadian brokers can convince them to do this deal then I have a bridge to sell them. It is a super value add bridge and it only costs $40million lol


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse